T1	intervention 0 11	Amisulpride
T4	control 812 819	placebo
T5	eligibility 541 662	Chemotherapy-naïve patients receiving cisplatin ≥ 70 mg/m2 or an anthracycline-cyclophosphamide regimen for breast cancer
T6	outcome-Measure 949 971	complete response (CR)
T7	total-participants 1042 1064	Three hundred eighteen
T8	outcome 1103 1121	CR rate (24-120 h)
T9	cv-bin-percent 1126 1129	20%
T10	iv-bin-percent 1147 1150	46%
T11	outcome 1262 1296	Emesis, nausea and 0-120-h CR rate
T12	outcome 1466 1487	delayed phase CR rate
T13	cv-bin-percent 1492 1495	44%
T14	iv-bin-percent 1509 1512	75%
T2	condition 21 40	nausea and vomiting
